Stock Events

Acrivon Therapeutics 

$9.75
16
+$0.13+1.4% Today

Statistics

Day High
9.76
Day Low
-
52W High
14.3
52W Low
3.19
Volume
66,693
Avg. Volume
2,181,190
Mkt Cap
220.6M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

26MarExpected
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.74
-0.49
-0.25
0
Expected EPS
-0.72
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACRV. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

16.5$Average Price Target
The highest estimate is $20.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

About

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Show more...
CEO
Employees
58
Country
US
ISIN
US0048901096

Listings